LiMM Therapeutics, a spin-off of iMM focused in developing a new class of immunotherapeutic drugs for cancer, inflammatory and metabolic diseases, was the only biotech company in Portugal selected for the EIC Accelerator programme, receiving 12.5M€.
LiMM’s research team has identified several candidate drugs to mediate the effects of immune response to injury. In pre-clinical tests with animal models, the promising results obtained demonstrated a high rate of success in reversing acute kidney injury and inflammation, a deadly condition with no available treatment.
The EIC grant will enable further development of these drugs by supporting the safety studies in animals, as well as phase one and phase two clinical studies of renal disease in humans.